Understanding the Market | CSPC PHARMA rose nearly 3% as Mesalazine enteric-coated tablets received drug registration approval, further enriching the product line in the field of immune system therapy
CSPC PHARMA rose nearly 3%, as of the time of publication, it increased by 2.04%, trading at HKD 8.02, with a transaction volume of HKD 311 million. In terms of news, recently, CSPC PHARMA announced that its developed mesalazine enteric-coated tablets (0.5g) have obtained the drug registration approval issued by the National Medical Products Administration of the People's Republic of China, and are considered to have passed the consistency evaluation of quality and efficacy for generic drugs. Mesalazine primarily exerts its therapeutic effect by regulating inflammation-related indicators that cause intestinal mucosal inflammation, inhibiting the synthesis of inflammatory prostaglandins and the formation of inflammatory mediators leukotrienes, thereby achieving anti-inflammatory effects, with better therapeutic effects on the connective tissue of inflamed intestinal walls. This product is suitable for the treatment of ulcerative colitis, including treatment during acute episodes and maintenance therapy to prevent recurrence, as well as for the treatment of acute episodes of Crohn's disease. This product has a significant inhibitory effect on intestinal wall inflammation and is a widely used aminosalicylate anti-inflammatory drug globally. The approval of this product will further enrich the group's product line in the field of immune system therapy
According to Zhitong Finance APP, CSPC PHARMA (01093) rose nearly 3%, and as of the time of writing, it was up 2.04%, trading at HKD 8.02, with a transaction volume of HKD 311 million.
In terms of news, recently, CSPC PHARMA announced that its developed mesalazine enteric-coated tablets (0.5g) have obtained the drug registration approval issued by the National Medical Products Administration of the People's Republic of China, and are considered to have passed the consistency evaluation of quality and efficacy for generic drugs.
Mesalazine primarily exerts its therapeutic effect by regulating inflammation-related indicators that cause intestinal mucosal inflammation, inhibiting the synthesis of inflammatory prostaglandins and the formation of inflammatory mediators leukotrienes, thereby achieving anti-inflammatory effects. It is particularly effective in treating the connective tissue of inflamed intestinal walls. This product is suitable for the treatment of ulcerative colitis, including treatment during acute episodes and maintenance therapy to prevent recurrence, as well as for treating acute episodes of Crohn's disease. The product has a significant inhibitory effect on intestinal wall inflammation and is a widely used aminosalicylate anti-inflammatory drug globally.
The approval of this product will further enrich the group's product line in the field of immune system therapy
